Gene Mutation Discovered in Blood Disorder Aplastic Anemia
By LabMedica International staff writers Posted on 07 Oct 2014 |
Image: Photomicrograph of a hypocellular bone marrow biopsy, due to lack of hematopoietic cells, from a patient with aplastic anemia (Photo courtesy of the Autonomous University of Zacatecas).
A gene mutation has been discovered that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells.
Telomerase is a ribonucleoprotein enzyme that is necessary for overcoming telomere shortening in human germ and stem cells. Mutations in telomerase or other telomere maintenance proteins can lead to diseases characterized by depletion of hematopoietic stem cells and bone marrow failure.
Scientists at the Children's Hospital of Philadelphia (PA, USA) working with international colleagues investigated the family of a patient who had presented with severe thrombocytopenia and macrocytosis, and has been diagnosed with aplastic anemia. The family history includes other cases of bone marrow failure, as well as oral carcinoma and leukemia. Peripheral blood DNA was available from the patient, her parents, and maternal grandparents.
Whole exome sequencing was performed and the exonic regions were captured using SureSelect Human All Exon kit (Agilent; Santa Clara, CA, USA) and pair-end sequencing was carried out on HiSeq 2000 machines (Illumina; San Diego, CA, USA). A Telomere Flow-Fluorescence In Situ Hybridization (Flow-FISH) was performed and the subsequent flow cytometry was performed on a FACS CANTO II (BD Biosciences; San Jose, CA, USA). Other complimentary methodologies were also used to corroborate the initial findings.
The 18 year-old patient, her mother and maternal grandmother presented with bone marrow failure of varying severity, and their decreasing ages of presentation in successive generations suggested disease anticipation. The team found that that the mutation in Adrenocortical Dysplasia Homolog gene (ACD) alters the telomere-binding protein tripeptidyl peptidase 1 (TPP1), disrupting the interactions between telomere and telomerase. Without access to telomerase to help maintain telomeres, blood cells lose their structural integrity and die, resulting in bone marrow failure.
Hakon Hakonarson, MD, PhD, the director of the Center for Applied Genomics, and study co-leader, said, “Identifying this causal defect may help suggest future molecular-based treatments that bypass the gene defect and restore blood cell production. This improved understanding of the underlying molecular mechanisms may suggest new approaches to treating disorders such as aplastic anemia. For instance, investigators may identify other avenues for recruiting telomerase to telomeres to restore its protective function.” The study was published on September 9, 2014, in the journal Blood.
Related Links:
Children's Hospital of Philadelphia
Agilent
Illumina
Telomerase is a ribonucleoprotein enzyme that is necessary for overcoming telomere shortening in human germ and stem cells. Mutations in telomerase or other telomere maintenance proteins can lead to diseases characterized by depletion of hematopoietic stem cells and bone marrow failure.
Scientists at the Children's Hospital of Philadelphia (PA, USA) working with international colleagues investigated the family of a patient who had presented with severe thrombocytopenia and macrocytosis, and has been diagnosed with aplastic anemia. The family history includes other cases of bone marrow failure, as well as oral carcinoma and leukemia. Peripheral blood DNA was available from the patient, her parents, and maternal grandparents.
Whole exome sequencing was performed and the exonic regions were captured using SureSelect Human All Exon kit (Agilent; Santa Clara, CA, USA) and pair-end sequencing was carried out on HiSeq 2000 machines (Illumina; San Diego, CA, USA). A Telomere Flow-Fluorescence In Situ Hybridization (Flow-FISH) was performed and the subsequent flow cytometry was performed on a FACS CANTO II (BD Biosciences; San Jose, CA, USA). Other complimentary methodologies were also used to corroborate the initial findings.
The 18 year-old patient, her mother and maternal grandmother presented with bone marrow failure of varying severity, and their decreasing ages of presentation in successive generations suggested disease anticipation. The team found that that the mutation in Adrenocortical Dysplasia Homolog gene (ACD) alters the telomere-binding protein tripeptidyl peptidase 1 (TPP1), disrupting the interactions between telomere and telomerase. Without access to telomerase to help maintain telomeres, blood cells lose their structural integrity and die, resulting in bone marrow failure.
Hakon Hakonarson, MD, PhD, the director of the Center for Applied Genomics, and study co-leader, said, “Identifying this causal defect may help suggest future molecular-based treatments that bypass the gene defect and restore blood cell production. This improved understanding of the underlying molecular mechanisms may suggest new approaches to treating disorders such as aplastic anemia. For instance, investigators may identify other avenues for recruiting telomerase to telomeres to restore its protective function.” The study was published on September 9, 2014, in the journal Blood.
Related Links:
Children's Hospital of Philadelphia
Agilent
Illumina
Latest Molecular Diagnostics News
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer